Key Highlights

  • SciSparc (NASDAQ:SPRC) traded at USD 0.80, down 37.98%, in pre-market trading on Tuesday, October 27, 2026, after a Form 6-K of Monday, October 26, 2026 disclosed the repricing of warrants to USD 1.00 per share.
  • The filing covers warrants over up to 405,728 ordinary shares, issued on Thursday, February 12, 2026 at USD 4.929, with expected gross proceeds of about USD 405,728 and closing on or about Tuesday, October 27, 2026.
  • The company announced on Thursday, October 15, 2026 a transformation into agentic AI powered technologies, and its NeuroThera Labs subsidiary completed manufacturing and batch release for the SCI-110 Phase IIb Tourette trial on Thursday, October 22, 2026.
  • The filing reported no operating results or cash balance, and the pre-market price sits below the USD 1.00 exercise price. Pre-market quotes are thinly traded and can change before the open.

The Pre-Market Move and Its Catalyst

SciSparc (NASDAQ:SPRC), an Israeli clinical-stage pharmaceutical and intellectual property company focused on cannabinoid-based technologies, traded at USD 0.80, down 37.98%, in pre-market trading on Tuesday, October 27, 2026, according to a pre-market snapshot. The snapshot implies a prior close of about USD 1.29, by simple arithmetic. A Form 6-K filed on Monday, October 26, 2026 disclosed an inducement offer letter with a single warrant holder, under which the holder agreed to exercise warrants over up to 405,728 ordinary shares for cash at a reduced USD 1.00 per share, against the original USD 4.929. The company expects gross proceeds of about USD 405,728 for working capital, with closing on or about Tuesday, October 27, 2026.

Why the Repricing and Recent Updates Matter

An inducement offer lowers the exercise price of existing warrants in return for immediate cash exercise, which adds shares to the float at a discount to the earlier terms. The pre-market quote of USD 0.80 sits below the new USD 1.00 exercise price, an observation from two published figures, and the fall appears consistent with dilution and pricing pressure, an inference. The filing reported no operating results or cash balance. Earlier updates include the announcement of Thursday, October 15, 2026 of a move into agentic AI technologies and the plan of Monday, October 19, 2026 to focus on AI cybersecurity and finance. On Tuesday, August 18, 2026, NeuroThera completed a CAD 5.4 million financing, in which SciSparc invested CAD 2.7 million for 22.5 million units at CAD 0.12.

Risks and What to Watch

The bull reading rests on the modest cash inflow, the value attributed by the company to its stake of about 44.6% in NeuroThera, near CAD 30 million, and the completed trial supply for the SCI-110 Phase IIb Tourette trial. The bear reading rests on repeated dilution through warrant repricing, a share price below USD 1.00 and a strategic pivot from cannabinoid medicines to artificial intelligence, a change of business model that carries execution risk. The SCI-210 autism trial had enrolled 26 of a planned 60 children by the announcement of Monday, August 31, 2026. Named risks are dilution, Nasdaq minimum bid price compliance, liquidity and strategic uncertainty. Investors should watch the closing of the exercise, any further financing, the Federal Reserve decision of Wednesday, October 28, 2026 and the next shipment of trial material.

Where Things Stand

The answer is that SciSparc (NASDAQ:SPRC) fell 37.98% pre-market to USD 0.80 after the Form 6-K of Monday, October 26, 2026 disclosed warrant repricing to USD 1.00, and the fall appears consistent with dilution, an inference. The key number is gross proceeds of about USD 405,728 against the original exercise price of USD 4.929. The next catalysts are the expected closing on or about Tuesday, October 27, 2026 and the Federal Reserve decision of Wednesday, October 28, 2026, which follows the rate rise of Wednesday, September 16, 2026. Pre-market prices are snapshots and can change, and this is not investment advice.